Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel
Brian Cheng

Brian Cheng Analyst Performance

Biotech Analyst at JPMorgan Chase & Co.

Brian Cheng is a stock analyst at JPMorgan Chase & Co. focused in the medical sector, covering 26 publicly traded companies. Over the past year, Brian Cheng has issued 32 stock ratings, including buy, hold, and sell recommendations. While full access to Brian Cheng's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Brian Cheng's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
41 Last 1 Years
Buy Recommendations
68.29% 28 Buy Ratings
Companies Covered
26 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy68.3%28 ratings
Hold22.0%9 ratings
Sell9.8%4 ratings

Out of 41 total stock ratings issued by Brian Cheng at JPMorgan Chase & Co., the majority (68.3%) have been Buy recommendations, followed by 22.0% Hold and 9.8% Sell.

Best & Worst Calls

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
26 companies

Brian Cheng, an analyst at JPMorgan Chase & Co., currently covers 26 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
24 companies		92.3%
Manufacturing
2 companies		7.7%

Brian Cheng of JPMorgan Chase & Co. specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
21 companies		80.8%
MED - DRUGS
2 companies		7.7%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
1 company		3.8%
MED INSTRUMENTS
1 company		3.8%
PHARMACEUTICAL PREPARATIONS
1 company		3.8%

Brian Cheng's Ratings History at JPMorgan Chase & Co.

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
Export
CompanyReport DateActionReport Date Price12-Month
Price Target		Rating12-Month
Price & ROI		Details
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
5/14/2026Lower Price Target$5.23$26.00Overweight
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
5/13/2026Lower Price Target$10.44$29.00Overweight
CG Oncology, Inc. stock logo
CGON
CG Oncology
5/11/2026Boost Price Target$69.11$96.00Overweight
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
5/11/2026Boost Price Target$20.30$31.00Overweight
Xencor, Inc. stock logo
XNCR
Xencor
5/11/2026Boost Price Target$12.83$14.00Neutral
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
5/1/2026Initiated Coverage$73.48$88.00Overweight
CG Oncology, Inc. stock logo
CGON
CG Oncology
4/17/2026Boost Price Target$68.99$91.00Overweight
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
4/16/2026Upgrade$2.17Neutral
Xencor, Inc. stock logo
XNCR
Xencor
3/24/2026Reiterated Rating$12.05$13.00Neutral
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3/19/2026Boost Price Target$101.85$106.00Overweight
Read now. Do not delete. You’ve been warned. (Ad)

Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.tc pixel

Don’t be left behind. Click here now.
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3/4/2026Initiated Coverage$6.15$27.00Overweight
EIKN
Eikon Therapeutics
3/2/2026Initiated Coverage$13.78$29.00Overweight
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
2/2/2026Lower Price Target$29.10$46.00Overweight
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
12/10/2025Boost Price Target$87.77$125.00Overweight
OPKO Health, Inc. stock logo
OPK
OPKO Health
11/20/2025Initiated Coverage$1.31Neutral
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
11/7/2025Reiterated Rating$12.32$5.00Underweight
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
11/7/2025Boost Price Target$79.83$81.00Overweight
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
11/6/2025Boost Price Target$61.38$82.00Overweight
Xencor, Inc. stock logo
XNCR
Xencor
11/6/2025Lower Price Target$14.00$18.00Overweight
Zymeworks Inc. stock logo
ZYME
Zymeworks
10/16/2025Boost Price Target$18.62$23.00Overweight
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
10/10/2025Reiterated Rating$1.51Underweight
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
10/10/2025Reiterated Rating$1.54Underweight
Absci Corporation stock logo
ABSI
Absci
10/2/2025Initiated Coverage$3.13Overweight
Immunovant, Inc. stock logo
IMVT
Immunovant
9/30/2025Lower Price Target$16.06$33.00Overweight
CG Oncology, Inc. stock logo
CGON
CG Oncology
9/26/2025Boost Price Target$36.48$47.00Overweight
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
9/18/2025Initiated Coverage$59.07$70.00Overweight
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
9/18/2025Boost Price Target$15.42$20.00Overweight
Precigen, Inc. stock logo
PGEN
Precigen
8/15/2025Upgrade$1.85Neutral
Immunovant, Inc. stock logo
IMVT
Immunovant
8/12/2025Lower Price Target$15.26$37.00Overweight
Immunome, Inc. stock logo
IMNM
Immunome
8/7/2025Lower Price Target$9.87$22.00Overweight
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
8/4/2025Reiterated Rating$1.08Neutral
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
6/2/2025Reiterated Rating$127.71$129.00Neutral
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
5/13/2025Downgrade$8.02$8.00Neutral
CG Oncology, Inc. stock logo
CGON
CG Oncology
5/2/2025Initiated Coverage$27.74$41.00Overweight
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
3/27/2025Initiated Coverage$18.37Overweight
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
3/6/2025Lower Price Target$7.11$15.00Overweight
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3/4/2025Boost Price Target$38.50$57.00Overweight
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
2/28/2025Reiterated Rating$10.86$13.00Neutral
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
2/4/2025Boost Price Target$37.66$53.00Overweight
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
2/4/2025Boost Price Target$112.35$129.00Overweight
Giving “2022 pre-ChatGPT” vibes (but 10x bigger) (Ad)

When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd could trigger a comparable wealth event - tied to a Tesla technology reveal Elon Musk has called '10x bigger than the largest product in history.' Analyst Matt Monaco - who previously identified the crypto and AI mega trends early - has released a full briefing on how to get positioned before the potential July 22nd launch date. Past performance doesn't indicate future results, and all trading carries risk.tc pixel

Access Matt Monaco's full briefing before the July 22nd reveal
CARGO Therapeutics, Inc. stock logo
CRGX
CARGO Therapeutics
1/30/2025Downgrade$13.19Underweight

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Top Stock Recommendations by Brokerage